Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

I²CNER Seminar Series 2015

Une énergie renouvelable est une énergie qui utilise des ressources naturelles, renouvelées plus rapidement qu'elles ne sont consommées. Energies solaire, hydraulique, géothermique, l'éolienne sont des énergies renouvelables. Cette collection de films, destinée à tout public, trouve son inspiration dans les travaux de recherche pluridisciplinaires menés dans les laboratoires de chimie : matériaux, cellules, catalyse, piles …. Elle illustre quelques uns des principes, des réalisations et des utilisations des énergies renouvelables. Pour tout public.

Les énergies renouvelables

Concevoir et élaborer des matériaux inorganiques et/ou hybrides originaux permettant de développer des réponses innovantes aux préoccupations sociétales dans les domaines de l'environnement, l'énergie et de la médecine...

Chimie des matériaux

Novidades da química e ciências, temas do cotidiano, bate-papo descontraído, conversas sobre experiências na vida acadêmica.

Química do dia a dia e divulgação científica, você encontra aqui!

Dúvides, sugestões e caneladas através do e-mail: oquimicast@gmail.com

Chave PIX para apoiar o projeto: quimicastpix@gmail.com

Novidades da química e ciências, temas do cotidiano, bate-papo descontraído, conversas sobre experiências na vida acadêmica. Química do dia a dia e divulgação científica, você encontra aqui! Dúvides, sugestões e caneladas através do e-mail: oquimicast@gmail.com Chave PIX para apoiar o projeto: quimicastpix@gmail.com

QuimiCast

Consigli, approfondimenti e peripezie di una farmacista digitale.

Pillole di Alice Pharmacist

U.S. Congressional Representative Ben McAdams, D-UT talks about his experiences in Washington, D.C. during his new job as congressman from Utah’s 4th district.

WashingTown

A podcast dedicated in telling the whole world about the greatness of Organic Chemistry

Organic Chemistricks

Spring 2011 - UCL's Lunch Hour Lecture Series is an opportunity for anyone to sample the exceptional research work taking place at the university, in bite-size chunks. Speakers are drawn from across UCL and lectures frequently showcase new research and recent academic publications. Lunch Hour Lectures require no pre-booking, are free to attend and are open to anyone on a first-come, first-served basis.

Lunch Hour Lectures - Spring 2011 - Audio

Welcome to ALD Stories, a series of conversations where we share the untold stories of atomic layer deposition and the people behind the technology.

ALD stories podcast

Preclase química

Nações Emergentes

Profesionalismo

Este podcast tiene la intención no solo de dar a conocer nuestros productos y servicios, sino también generar una comunidad científica apasionada por compartir nuevos conocimientos y va dirigido a todos aquellos intrépidos que siempre quieren saber más.

Este podcast tiene la intención no solo de dar a conocer nuestros productos y servicios, sino también generar una comunidad científica apasionada por compartir nuevos conocimientos y va dirigido a todos aquellos intrépidos que siempre quieren saber más.

WIST Podcast

TEMA DUREZA

@cosasquimicas

Poetry through the eyes of a microbiologist

Meet Minerva, The POET and Microbiologist

The original soundtrack for my soul and dreams

Magic

Sobreviviendo a la COVID-19 en México, el remedio olvidado

«Химия и Технологии» - это специальный проект РХТУ им. Д. И. Менделеева о науке и не только. Новейшие разработки в областях медицины, энергетики, авиастроения, микрофлюидики, а также ответы на самые распространённые вопросы о химии, - всё это аудиоподкаст «ХиТ». Мы расскажем просто о сложном. Приятного прослушивания!

ХиТ: Химия и Технологии

Mein Name ist Clara Müller und ich habe 2022 mein Journalismus Studium beendet. In diesem Podcast werde ich mit der Chemie Industrie in den Dialog kommen. In zehn Minuten werde ich fünf Aspekte eines Themas beleuchten und mit einem Gast besprechen. Die Community darf entscheiden über welches Thema. Eure gewünschten Themen könnt ihr auf https://www.transformation.nrw/podcast mitteilen.
Ihr entscheidet, Clara fragt...!

Mein Name ist Clara Müller und ich habe 2022 mein Journalismus Studium beendet. In diesem Podcast werde ich mit der Chemie Industrie in den Dialog kommen. In zehn Minuten werde ich fünf Aspekte eines Themas beleuchten und mit einem Gast besprechen. Die Community darf entscheiden über welches Thema. Eure gewünschten Themen könnt ihr auf https://www.transformation.nrw/podcast mitteilen. Ihr entscheidet, Clara fragt...!

Clara fragt...!

Hay química por todo lado por todo lugar

Ciencia en el aire

The Chemistry Connections Podcast is a student-run podcast that examines the chemistry behind real-world topics that interest Mr. Johnson's AP Chemistry students.  Students talk about an array of topics such as food, art, history, medicine, and much much more.

The Chemistry Connections Podcast is a student-run podcast that examines the chemistry behind real-world topics that interest Mr. Johnson's AP Chemistry students. Students talk about an array of topics such as food, art, history, medicine, and much much more.

Chemistry Connections

호주 과학계를 이끌 차세대 호주한인 과학자들의 첨단 연구 분야를 알아봅니다.

차세대 호주한인 과학자들

Bernard Meunier est directeur de recherche émérite au CNRS (de classe exceptionnelle) au Laboratoire de chimie de coordination du CNRS à Toulouse et Distinguished Professor du département de Chimie de l'université de Technologie de Guangdong à Canton (Chine).

Bernard Meunier est directeur de recherche émérite au CNRS (de classe exceptionnelle) au Laboratoire de chimie de coordination du CNRS à Toulouse et Distinguished Professor du département de Chimie de l'université de Technologie de Guangdong à Canton (Chine).

Innovation technologique Liliane Bettencourt (2014-2015) - Bernard Meunier

MDMA (3,4-methylenedioxymethamphetamine), known commonly as Ecstasy or Molly, has transitioned from a popular recreational drug to a promising therapeutic tool. The unique psychoactive properties of MDMA, which enhance empathy and reduce fear, have made it a powerful aid in psychotherapy, particularly for treating severe psychological conditions like PTSD. This article delves into the historical context, mechanism of action, therapeutic applications, clinical trials, safety considerations, and future prospects of MDMA in therapeutic settings. MDMA has a fascinating history that spans over a century. It was first synthesized by the German pharmaceutical company Merck in 1912 as part of their research into blood-clotting medications. However, the psychoactive properties of MDMA remained unknown for decades. It wasn't until the 1970s that American chemist Alexander Shulgin re-synthesized MDMA in his lab. Shulgin, known for his pioneering work in psychedelic chemistry, recognized the unique effects of MDMA on the human psyche. Shulgin shared his findings with psychotherapist Leo Zeff, who saw the potential of MDMA as a therapeutic aid. Zeff introduced MDMA to the psychotherapy community, where it quickly gained popularity as a tool for facilitating emotional breakthroughs and enhancing the therapeutic alliance. Throughout the late 1970s and early 1980s, MDMA was used by a network of therapists who believed in its ability to catalyze healing. However, MDMA's rising popularity extended beyond therapeutic circles. It became a sought-after recreational drug, particularly in the rave and club scene. The increasing non-medical use of MDMA led to concerns about its potential for abuse and neurotoxicity. In 1985, the U.S. Drug Enforcement Administration (DEA) stepped in and classified MDMA as a Schedule I controlled substance. This classification placed severe restrictions on the legal use of MDMA, effectively halting its use in therapy and limiting research into its potential benefits. Despite the legal obstacles, a dedicated group of researchers and advocates continued to explore the therapeutic potential of MDMA. Organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) played a crucial role in advancing MDMA research, conducting clinical trials, and advocating for policy changes to facilitate its medical use. To understand how MDMA exerts its therapeutic effects, it's essential to examine its mechanism of action in the brain. MDMA primarily acts on three key neurotransmitter systems: serotonin, dopamine, and norepinephrine. When MDMA enters the brain, it causes a significant release of these neurotransmitters, leading to a cascade of psychological and physiological effects. Serotonin is perhaps the most important neurotransmitter involved in MDMA's action. MDMA causes a massive surge in serotonin levels, which is responsible for the drug's mood-elevating and prosocial effects. This increase in serotonin leads to feelings of euphoria, emotional warmth, and increased empathy. It allows individuals to connect with their emotions and with others in a profound way, which can be particularly beneficial in a therapeutic context. Dopamine, often associated with reward and motivation, is also affected by MDMA. The release of dopamine contributes to the pleasurable and energizing effects of the drug. It can enhance focus and engagement during therapy sessions, helping patients stay present and committed to the therapeutic process. Norepinephrine, a neurotransmitter involved in the body's stress response, is also increased by MDMA. This can lead to some of the physical effects of the drug, such as increased heart rate and blood pressure. However, the release of norepinephrine also plays a role in the emotional impact of MDMA. It can heighten emotional arousal and help individuals access and process difficult emotions. In addition to its effects on these neurotransmitters, MDMA has been shown to increase the release of oxytocin, often referred to as the "love hormone." Oxytocin is involved in social bonding, trust, and emotional regulation. The surge of oxytocin induced by MDMA can create a profound sense of connection and trust between the patient and therapist, fostering a strong therapeutic alliance. The combination of these neurochemical effects creates a unique psychological state characterized by reduced fear and defensiveness, increased empathy and emotional openness, and a heightened capacity for introspection and self-reflection. This state is particularly conducive to therapeutic work, allowing patients to access and process traumatic memories, emotions, and beliefs in a way that may not be possible under normal circumstances. It's important to note that the therapeutic effects of MDMA are not solely due to its pharmacological action. The drug is used as part of a carefully designed therapeutic protocol that includes preparatory sessions, MDMA-assisted sessions, and integrative follow-up sessions. The supportive and safe environment provided by trained therapists is crucial for maximizing the therapeutic potential of MDMA and minimizing the risks associated with its use. The therapeutic applications of MDMA are diverse and far-reaching, with the potential to address a range of mental health conditions. The most well-established and researched application of MDMA is in the treatment of post-traumatic stress disorder (PTSD). PTSD is a debilitating condition that can develop after exposure to a traumatic event, such as combat, sexual assault, or natural disasters. It is characterized by symptoms like intrusive memories, avoidance of trauma-related stimuli, negative alterations in cognition and mood, and hyperarousal. Traditional treatments for PTSD, such as cognitive-behavioral therapy and medication, have limitations and are not effective for everyone. MDMA-assisted psychotherapy has emerged as a promising alternative for individuals with PTSD, particularly those who have not responded to conventional treatments. The unique properties of MDMA, such as reducing fear and increasing empathy, make it well-suited for treating the core symptoms of PTSD. During MDMA-assisted therapy sessions, patients are able to revisit and process traumatic memories in a safe and supportive environment. The drug reduces the fear and emotional numbing associated with these memories, allowing patients to engage with them in a more constructive way. They can access and express emotions that may have been suppressed or avoided, leading to a cathartic release and a new perspective on their experiences. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been at the forefront of research on MDMA-assisted therapy for PTSD. Their clinical trials have yielded impressive results, with a significant proportion of participants experiencing long-lasting improvements in their symptoms. In fact, the results have been so promising that the FDA has granted MDMA-assisted therapy a Breakthrough Therapy designation for PTSD, accelerating its path to approval. A recent article in The New York Times highlighted the anticipation surrounding the FDA's potential approval of MDMA-assisted therapy for PTSD. The article emphasized the transformative potential of this treatment, which could provide relief for the millions of individuals suffering from PTSD worldwide. It also underscored the importance of continued research and responsible use of MDMA in therapeutic settings. While PTSD is currently the primary focus of MDMA therapy research, there is growing interest in exploring its potential for other mental health conditions. Preliminary studies suggest that MDMA could be beneficial for treating depression, anxiety, and social anxiety in autistic adults. Depression, characterized by persistent low mood, loss of interest, and feelings of hopelessness, is a widespread and debilitating mental health condition. Current treatments, such as antidepressant medications and psychotherapy, are not always effective, leaving many individuals struggling with ongoing symptoms. MDMA's ability to promote emotional openness, self-compassion, and insight could make it a valuable tool in the treatment of depression. Similarly, MDMA's prosocial effects and reduction of fear could be particularly useful for individuals with anxiety disorders, including social anxiety disorder. By reducing the emotional barriers that prevent individuals from engaging in social situations, MDMA could facilitate exposure therapy and help individuals develop more adaptive coping strategies. Autism spectrum disorder (ASD) is another area where MDMA therapy shows promise. Many individuals with ASD struggle with social interactions and communication, which can lead to anxiety and isolation. MDMA's ability to enhance empathy and reduce social fears could help autistic adults navigate social situations more effectively and form meaningful connections with others. As research continues to expand, it's likely that new therapeutic applications of MDMA will emerge. The unique properties of this drug, combined with the supportive environment of psychotherapy, hold significant potential for addressing a range of mental health challenges. The resurgence of interest in MDMA as a therapeutic tool has been driven by a growing body of clinical research. In recent years, several landmark clinical trials have provided compelling evidence for the efficacy and safety of MDMA-assisted therapy, particularly for the treatment of PTSD. The most notable clinical trials have been conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization dedicated to the development of medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. MAPS has been at the forefront of MDMA research for over three decades, working tirelessly to advance the scientific understanding and clini

MDMA (3,4-methylenedioxymethamphetamine), known commonly as Ecstasy or Molly, has transitioned from a popular recreational drug to a promising therapeutic tool. The unique psychoactive properties of MDMA, which enhance empathy and reduce fear, have made it a powerful aid in psychotherapy, particularly for treating severe psychological conditions like PTSD. This article delves into the historical context, mechanism of action, therapeutic applications, clinical trials, safety considerations, and future prospects of MDMA in therapeutic settings. MDMA has a fascinating history that spans over a century. It was first synthesized by the German pharmaceutical company Merck in 1912 as part of their research into blood-clotting medications. However, the psychoactive properties of MDMA remained unknown for decades. It wasn't until the 1970s that American chemist Alexander Shulgin re-synthesized MDMA in his lab. Shulgin, known for his pioneering work in psychedelic chemistry, recognized the unique effects of MDMA on the human psyche. Shulgin shared his findings with psychotherapist Leo Zeff, who saw the potential of MDMA as a therapeutic aid. Zeff introduced MDMA to the psychotherapy community, where it quickly gained popularity as a tool for facilitating emotional breakthroughs and enhancing the therapeutic alliance. Throughout the late 1970s and early 1980s, MDMA was used by a network of therapists who believed in its ability to catalyze healing. However, MDMA's rising popularity extended beyond therapeutic circles. It became a sought-after recreational drug, particularly in the rave and club scene. The increasing non-medical use of MDMA led to concerns about its potential for abuse and neurotoxicity. In 1985, the U.S. Drug Enforcement Administration (DEA) stepped in and classified MDMA as a Schedule I controlled substance. This classification placed severe restrictions on the legal use of MDMA, effectively halting its use in therapy and limiting research into its potential benefits. Despite the legal obstacles, a dedicated group of researchers and advocates continued to explore the therapeutic potential of MDMA. Organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) played a crucial role in advancing MDMA research, conducting clinical trials, and advocating for policy changes to facilitate its medical use. To understand how MDMA exerts its therapeutic effects, it's essential to examine its mechanism of action in the brain. MDMA primarily acts on three key neurotransmitter systems: serotonin, dopamine, and norepinephrine. When MDMA enters the brain, it causes a significant release of these neurotransmitters, leading to a cascade of psychological and physiological effects. Serotonin is perhaps the most important neurotransmitter involved in MDMA's action. MDMA causes a massive surge in serotonin levels, which is responsible for the drug's mood-elevating and prosocial effects. This increase in serotonin leads to feelings of euphoria, emotional warmth, and increased empathy. It allows individuals to connect with their emotions and with others in a profound way, which can be particularly beneficial in a therapeutic context. Dopamine, often associated with reward and motivation, is also affected by MDMA. The release of dopamine contributes to the pleasurable and energizing effects of the drug. It can enhance focus and engagement during therapy sessions, helping patients stay present and committed to the therapeutic process. Norepinephrine, a neurotransmitter involved in the body's stress response, is also increased by MDMA. This can lead to some of the physical effects of the drug, such as increased heart rate and blood pressure. However, the release of norepinephrine also plays a role in the emotional impact of MDMA. It can heighten emotional arousal and help individuals access and process difficult emotions. In addition to its effects on these neurotransmitters, MDMA has been shown to increase the release of oxytocin, often referred to as the "love hormone." Oxytocin is involved in social bonding, trust, and emotional regulation. The surge of oxytocin induced by MDMA can create a profound sense of connection and trust between the patient and therapist, fostering a strong therapeutic alliance. The combination of these neurochemical effects creates a unique psychological state characterized by reduced fear and defensiveness, increased empathy and emotional openness, and a heightened capacity for introspection and self-reflection. This state is particularly conducive to therapeutic work, allowing patients to access and process traumatic memories, emotions, and beliefs in a way that may not be possible under normal circumstances. It's important to note that the therapeutic effects of MDMA are not solely due to its pharmacological action. The drug is used as part of a carefully designed therapeutic protocol that includes preparatory sessions, MDMA-assisted sessions, and integrative follow-up sessions. The supportive and safe environment provided by trained therapists is crucial for maximizing the therapeutic potential of MDMA and minimizing the risks associated with its use. The therapeutic applications of MDMA are diverse and far-reaching, with the potential to address a range of mental health conditions. The most well-established and researched application of MDMA is in the treatment of post-traumatic stress disorder (PTSD). PTSD is a debilitating condition that can develop after exposure to a traumatic event, such as combat, sexual assault, or natural disasters. It is characterized by symptoms like intrusive memories, avoidance of trauma-related stimuli, negative alterations in cognition and mood, and hyperarousal. Traditional treatments for PTSD, such as cognitive-behavioral therapy and medication, have limitations and are not effective for everyone. MDMA-assisted psychotherapy has emerged as a promising alternative for individuals with PTSD, particularly those who have not responded to conventional treatments. The unique properties of MDMA, such as reducing fear and increasing empathy, make it well-suited for treating the core symptoms of PTSD. During MDMA-assisted therapy sessions, patients are able to revisit and process traumatic memories in a safe and supportive environment. The drug reduces the fear and emotional numbing associated with these memories, allowing patients to engage with them in a more constructive way. They can access and express emotions that may have been suppressed or avoided, leading to a cathartic release and a new perspective on their experiences. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been at the forefront of research on MDMA-assisted therapy for PTSD. Their clinical trials have yielded impressive results, with a significant proportion of participants experiencing long-lasting improvements in their symptoms. In fact, the results have been so promising that the FDA has granted MDMA-assisted therapy a Breakthrough Therapy designation for PTSD, accelerating its path to approval. A recent article in The New York Times highlighted the anticipation surrounding the FDA's potential approval of MDMA-assisted therapy for PTSD. The article emphasized the transformative potential of this treatment, which could provide relief for the millions of individuals suffering from PTSD worldwide. It also underscored the importance of continued research and responsible use of MDMA in therapeutic settings. While PTSD is currently the primary focus of MDMA therapy research, there is growing interest in exploring its potential for other mental health conditions. Preliminary studies suggest that MDMA could be beneficial for treating depression, anxiety, and social anxiety in autistic adults. Depression, characterized by persistent low mood, loss of interest, and feelings of hopelessness, is a widespread and debilitating mental health condition. Current treatments, such as antidepressant medications and psychotherapy, are not always effective, leaving many individuals struggling with ongoing symptoms. MDMA's ability to promote emotional openness, self-compassion, and insight could make it a valuable tool in the treatment of depression. Similarly, MDMA's prosocial effects and reduction of fear could be particularly useful for individuals with anxiety disorders, including social anxiety disorder. By reducing the emotional barriers that prevent individuals from engaging in social situations, MDMA could facilitate exposure therapy and help individuals develop more adaptive coping strategies. Autism spectrum disorder (ASD) is another area where MDMA therapy shows promise. Many individuals with ASD struggle with social interactions and communication, which can lead to anxiety and isolation. MDMA's ability to enhance empathy and reduce social fears could help autistic adults navigate social situations more effectively and form meaningful connections with others. As research continues to expand, it's likely that new therapeutic applications of MDMA will emerge. The unique properties of this drug, combined with the supportive environment of psychotherapy, hold significant potential for addressing a range of mental health challenges. The resurgence of interest in MDMA as a therapeutic tool has been driven by a growing body of clinical research. In recent years, several landmark clinical trials have provided compelling evidence for the efficacy and safety of MDMA-assisted therapy, particularly for the treatment of PTSD. The most notable clinical trials have been conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization dedicated to the development of medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. MAPS has been at the forefront of MDMA research for over three decades, working tirelessly to advance the scientific understanding and clini

MDMA (3,4-methylenedioxymethamphetamine), known commonly as Ecstasy or Molly, has transitioned from a popular recreational drug to a promising therapeutic tool. The unique psychoactive properties of MDMA, which enhance empathy and reduce fear, have made it a powerful aid in psychotherapy, particularly for treating severe psychological conditions like PTSD. This article delves into the historical context, mechanism of action, therapeutic applications, clinical trials, safety considerations, and future prospects of MDMA in therapeutic settings. MDMA has a fascinating history that spans over a century. It was first synthesized by the German pharmaceutical company Merck in 1912 as part of their research into blood-clotting medications. However, the psychoactive properties of MDMA remained unknown for decades. It wasn't until the 1970s that American chemist Alexander Shulgin re-synthesized MDMA in his lab. Shulgin, known for his pioneering work in psychedelic chemistry, recognized the unique effects of MDMA on the human psyche. Shulgin shared his findings with psychotherapist Leo Zeff, who saw the potential of MDMA as a therapeutic aid. Zeff introduced MDMA to the psychotherapy community, where it quickly gained popularity as a tool for facilitating emotional breakthroughs and enhancing the therapeutic alliance. Throughout the late 1970s and early 1980s, MDMA was used by a network of therapists who believed in its ability to catalyze healing. However, MDMA's rising popularity extended beyond therapeutic circles. It became a sought-after recreational drug, particularly in the rave and club scene. The increasing non-medical use of MDMA led to concerns about its potential for abuse and neurotoxicity. In 1985, the U.S. Drug Enforcement Administration (DEA) stepped in and classified MDMA as a Schedule I controlled substance. This classification placed severe restrictions on the legal use of MDMA, effectively halting its use in therapy and limiting research into its potential benefits. Despite the legal obstacles, a dedicated group of researchers and advocates continued to explore the therapeutic potential of MDMA. Organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) played a crucial role in advancing MDMA research, conducting clinical trials, and advocating for policy changes to facilitate its medical use. To understand how MDMA exerts its therapeutic effects, it's essential to examine its mechanism of action in the brain. MDMA primarily acts on three key neurotransmitter systems: serotonin, dopamine, and norepinephrine. When MDMA enters the brain, it causes a significant release of these neurotransmitters, leading to a cascade of psychological and physiological effects. Serotonin is perhaps the most important neurotransmitter involved in MDMA's action. MDMA causes a massive surge in serotonin levels, which is responsible for the drug's mood-elevating and prosocial effects. This increase in serotonin leads to feelings of euphoria, emotional warmth, and increased empathy. It allows individuals to connect with their emotions and with others in a profound way, which can be particularly beneficial in a therapeutic context. Dopamine, often associated with reward and motivation, is also affected by MDMA. The release of dopamine contributes to the pleasurable and energizing effects of the drug. It can enhance focus and engagement during therapy sessions, helping patients stay present and committed to the therapeutic process. Norepinephrine, a neurotransmitter involved in the body's stress response, is also increased by MDMA. This can lead to some of the physical effects of the drug, such as increased heart rate and blood pressure. However, the release of norepinephrine also plays a role in the emotional impact of MDMA. It can heighten emotional arousal and help individuals access and process difficult emotions. In addition to its effects on these neurotransmitters, MDMA has been shown to increase the release of oxytocin, often referred to as the "love hormone." Oxytocin is involved in social bonding, trust, and emotional regulation. The surge of oxytocin induced by MDMA can create a profound sense of connection and trust between the patient and therapist, fostering a strong therapeutic alliance. The combination of these neurochemical effects creates a unique psychological state characterized by reduced fear and defensiveness, increased empathy and emotional openness, and a heightened capacity for introspection and self-reflection. This state is particularly conducive to therapeutic work, allowing patients to access and process traumatic memories, emotions, and beliefs in a way that may not be possible under normal circumstances. It's important to note that the therapeutic effects of MDMA are not solely due to its pharmacological action. The drug is used as part of a carefully designed therapeutic protocol that includes preparatory sessions, MDMA-assisted sessions, and integrative follow-up sessions. The supportive and safe environment provided by trained therapists is crucial for maximizing the therapeutic potential of MDMA and minimizing the risks associated with its use. The therapeutic applications of MDMA are diverse and far-reaching, with the potential to address a range of mental health conditions. The most well-established and researched application of MDMA is in the treatment of post-traumatic stress disorder (PTSD). PTSD is a debilitating condition that can develop after exposure to a traumatic event, such as combat, sexual assault, or natural disasters. It is characterized by symptoms like intrusive memories, avoidance of trauma-related stimuli, negative alterations in cognition and mood, and hyperarousal. Traditional treatments for PTSD, such as cognitive-behavioral therapy and medication, have limitations and are not effective for everyone. MDMA-assisted psychotherapy has emerged as a promising alternative for individuals with PTSD, particularly those who have not responded to conventional treatments. The unique properties of MDMA, such as reducing fear and increasing empathy, make it well-suited for treating the core symptoms of PTSD. During MDMA-assisted therapy sessions, patients are able to revisit and process traumatic memories in a safe and supportive environment. The drug reduces the fear and emotional numbing associated with these memories, allowing patients to engage with them in a more constructive way. They can access and express emotions that may have been suppressed or avoided, leading to a cathartic release and a new perspective on their experiences. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been at the forefront of research on MDMA-assisted therapy for PTSD. Their clinical trials have yielded impressive results, with a significant proportion of participants experiencing long-lasting improvements in their symptoms. In fact, the results have been so promising that the FDA has granted MDMA-assisted therapy a Breakthrough Therapy designation for PTSD, accelerating its path to approval. A recent article in The New York Times highlighted the anticipation surrounding the FDA's potential approval of MDMA-assisted therapy for PTSD. The article emphasized the transformative potential of this treatment, which could provide relief for the millions of individuals suffering from PTSD worldwide. It also underscored the importance of continued research and responsible use of MDMA in therapeutic settings. While PTSD is currently the primary focus of MDMA therapy research, there is growing interest in exploring its potential for other mental health conditions. Preliminary studies suggest that MDMA could be beneficial for treating depression, anxiety, and social anxiety in autistic adults. Depression, characterized by persistent low mood, loss of interest, and feelings of hopelessness, is a widespread and debilitating mental health condition. Current treatments, such as antidepressant medications and psychotherapy, are not always effective, leaving many individuals struggling with ongoing symptoms. MDMA's ability to promote emotional openness, self-compassion, and insight could make it a valuable tool in the treatment of depression. Similarly, MDMA's prosocial effects and reduction of fear could be particularly useful for individuals with anxiety disorders, including social anxiety disorder. By reducing the emotional barriers that prevent individuals from engaging in social situations, MDMA could facilitate exposure therapy and help individuals develop more adaptive coping strategies. Autism spectrum disorder (ASD) is another area where MDMA therapy shows promise. Many individuals with ASD struggle with social interactions and communication, which can lead to anxiety and isolation. MDMA's ability to enhance empathy and reduce social fears could help autistic adults navigate social situations more effectively and form meaningful connections with others. As research continues to expand, it's likely that new therapeutic applications of MDMA will emerge. The unique properties of this drug, combined with the supportive environment of psychotherapy, hold significant potential for addressing a range of mental health challenges. The resurgence of interest in MDMA as a therapeutic tool has been driven by a growing body of clinical research. In recent years, several landmark clinical trials have provided compelling evidence for the efficacy and safety of MDMA-assisted therapy, particularly for the treatment of PTSD. The most notable clinical trials have been conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization dedicated to the development of medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. MAPS has been at the forefront of MDMA research for over three decades, working tirelessly to advance the scientific understanding and clini

MDMA Therapy

Join host Kurt Stahle, “That Plastics Guy”, as he shares his knowledge and four decades of plastics industry experience with you; discussing, informing, interviewing, and having fun along the way.&nbsp; Please visit Simcoe Plastics at&nbsp; https://www.simcoeplastics.com/ Please click the LinkTree for all social feeds. <a href="https://linktr.ee/kurt_stahle">https://linktr.ee/kurt_stahle</a>

Join host Kurt Stahle, “That Plastics Guy”, as he shares his knowledge and four decades of plastics industry experience with you; discussing, informing, interviewing, and having fun along the way.  Please visit Simcoe Plastics at  https://www.simcoeplastics.com/ Please click the LinkTree for all social feeds. https://linktr.ee/kurt_stahle

Join host Kurt Stahle, “That Plastics Guy”, as he shares his knowledge and four decades of plastics industry experience with you; discussing, informing, interviewing, and having fun along the way.&nbsp; Please visit Simcoe Plastics at&nbsp; https://www.simcoeplastics.com/ Please click the LinkTree for all social feeds. <a href="https://linktr.ee/kurt_stahle" rel="noopener noreferrer">https://linktr.ee/kurt_stahle</a>

That Plastics Guy

&nbsp;Welcome to Pool Care 101 with your host, Al G. Free, the go-to source for all things swimming pool maintenance! Whether you're a new pool owner or just looking to brush up on the basics, Al G. is here every Wednesday at 9 PM Eastern to break down the essentials of pool care. From balancing chemicals and cleaning tips to troubleshooting common pool issues, Al G. covers it all in easy-to-understand, bite-sized episodes. Tune in each week to get practical advice, actionable tips, and expert insights that will help you keep your pool sparkling clean and swim-ready. Pool Care 101 – your weekly guide to pool perfection!&nbsp;

 Welcome to Pool Care 101 with your host, Al G. Free, the go-to source for all things swimming pool maintenance! Whether you're a new pool owner or just looking to brush up on the basics, Al G. is here every Wednesday at 9 PM Eastern to break down the essentials of pool care. From balancing chemicals and cleaning tips to troubleshooting common pool issues, Al G. covers it all in easy-to-understand, bite-sized episodes. Tune in each week to get practical advice, actionable tips, and expert insights that will help you keep your pool sparkling clean and swim-ready. Pool Care 101 – your weekly guide to pool perfection! 

Pool School

Smart Acids, a Univar Solutions podcast, is the source for product insights and current market moves related to chemical and specialty ingredient distribution—breaking it all down one boron at a time. Join hosts Andy Erickson and Chris Ernst for straightforward and honest chat that speaks to the why behind pricing and supply, delivered in a smart, fun and entertaining way. Learn more about Univar Solutions at UnivarSolutions.com.

Smart Acids, a Univar Solutions podcast, is the source for product insights and current market moves related to chemical and specialty ingredient distribution—breaking it all down one boron at a time. Join hosts Andy Erickson and Chris Ernst for straightforward and honest chat that speaks to the why behind pricing and supply, delivered in a smart, fun and entertaining way. Learn more about Univar Solutions at UnivarSolutions.com.

Smart Acids™

Los enlaces iónicos

Plastic. Climate. Future. enables engagement among industry members, climate activists, innovators, and the rest of world (the general public) to ultimately achieve positive changes related to plastic and the climate. 
In their podcast, Mat &amp; John host guests from these groups of stakeholders and talk about their views, activities and opinions to foster trustful communication and learn from each other. 
Check out more at www.plasticclimatefuture.com

Plastic. Climate. Future. enables engagement among industry members, climate activists, innovators, and the rest of world (the general public) to ultimately achieve positive changes related to plastic and the climate. In their podcast, Mat & John host guests from these groups of stakeholders and talk about their views, activities and opinions to foster trustful communication and learn from each other. Check out more at www.plasticclimatefuture.com

Plastic. Climate. Future.

Are you interested in learning about General Chemistry ! Are you passionate about science and want to learn about it in a fun and engaging way! Check out " Lecture-casts"- A Podcast Lecture Series in Chemistry" on Spotify! Don't forget to subscribe! We are grateful to have some of the best science educators and thought leaders! Thanks.

"Lecture-casts"- A Lecture Series on General Chemistry

A special segment on Money FM 89.3's Breakfast Show that brings you on an exclusive audio journey to the ends of the world, covering in-depth environment, natural history and climate change stories that intertwine with human life on Earth.

A special segment on Money FM 89.3's Breakfast Show that brings you on an exclusive audio journey to the ends of the world, covering in-depth environment, natural history and climate change stories that intertwine with human life on Earth.

Climate Connections

STEM-focused podcast from the Roanoke Valley Governor's School. Learn about students' STEM interests as they talk with classmates and share their passions.

STEM-focused podcast from the Roanoke Valley Governor's School. Learn about students' STEM interests as they talk with classmates and share their passions.

The RVGS Rat Chat

Welcome to CLEAN Chemicals, your go-to source for insightful discussions and expert perspectives on the chemical industry. 

Hosted by Aaron Lee, founder of Alchem Trading, a seasoned professional in the chemical industry, this podcast aims to demystifies chemicals, introduce innovative technologies, and educate listeners on how it all works.

Join us as we:
- Explore industry trends and developments.
- Feature interviews with top suppliers, researchers, and experts.
- Highlight cutting-edge technologies and products.
- Provide an insider's view of the chemical supply chain.
- Simplify complex chemical concepts for better understanding.

Welcome to CLEAN Chemicals, your go-to source for insightful discussions and expert perspectives on the chemical industry. Hosted by Aaron Lee, founder of Alchem Trading, a seasoned professional in the chemical industry, this podcast aims to demystifies chemicals, introduce innovative technologies, and educate listeners on how it all works. Join us as we: - Explore industry trends and developments. - Feature interviews with top suppliers, researchers, and experts. - Highlight cutting-edge technologies and products. - Provide an insider's view of the chemical supply chain. - Simplify complex chemical concepts for better understanding.

CLEAN Chemicals with Aaron Lee

In this episode of "<a target="_blank" rel="noopener noreferrer nofollow" href="https://bhumigrowthsolutions.com/">Bhumi Growth Solutions - Pest Control Revolution</a>," we delve into the transformative power of EmaGuard 5X and how it can help farmers achieve unparalleled crop yields. With Emamectin Benzoate 5% SG at its core, EmaGuard 5X is more than just an insecticide—it's a game-changer for modern agriculture.Join us as we explore the unique features and benefits of EmaGuard 5X, from its fast-acting pest control to its long-lasting protection. Discover how its innovative water-soluble granular formulation ensures even distribution and effective pest management across a variety of crops, including cotton, chillies, cabbage, okra, and tomatoes.We'll also hear from real farmers who have experienced the incredible results of using EmaGuard 5X, boosting their crop health and productivity while promoting sustainable farming practices. Our expert guests will share practical tips on application methods, dosage recommendations, and best practices to maximize the benefits of this revolutionary product.Tune in to "Maximizing Crop Yields with EmaGuard 5X" and learn how this cutting-edge insecticide can help you unlock the full potential of your fields, ensuring healthier crops and higher yields. Don't miss this in-depth discussion on taking your farming game to the next level!

In this episode of "Bhumi Growth Solutions - Pest Control Revolution," we delve into the transformative power of EmaGuard 5X and how it can help farmers achieve unparalleled crop yields. With Emamectin Benzoate 5% SG at its core, EmaGuard 5X is more than just an insecticide—it's a game-changer for modern agriculture. Join us as we explore the unique features and benefits of EmaGuard 5X, from its fast-acting pest control to its long-lasting protection. Discover how its innovative water-soluble granular formulation ensures even distribution and effective pest management across a variety of crops, including cotton, chillies, cabbage, okra, and tomatoes. We'll also hear from real farmers who have experienced the incredible results of using EmaGuard 5X, boosting their crop health and productivity while promoting sustainable farming practices. Our expert guests will share practical tips on application methods, dosage recommendations, and best practices to maximize the benefits of this revolutionary product. Tune in to "Maximizing Crop Yields with EmaGuard 5X" and learn how this cutting-edge insecticide can help you unlock the full potential of your fields, ensuring healthier crops and higher yields. Don't miss this in-depth discussion on taking your farming game to the next level!

In this episode of "<a href="https://bhumigrowthsolutions.com/" rel="noopener noreferrer">Bhumi Growth Solutions - Pest Control Revolution</a>," we delve into the transformative power of EmaGuard 5X and how it can help farmers achieve unparalleled crop yields. With Emamectin Benzoate 5% SG at its core, EmaGuard 5X is more than just an insecticide—it's a game-changer for modern agriculture.Join us as we explore the unique features and benefits of EmaGuard 5X, from its fast-acting pest control to its long-lasting protection. Discover how its innovative water-soluble granular formulation ensures even distribution and effective pest management across a variety of crops, including cotton, chillies, cabbage, okra, and tomatoes.We'll also hear from real farmers who have experienced the incredible results of using EmaGuard 5X, boosting their crop health and productivity while promoting sustainable farming practices. Our expert guests will share practical tips on application methods, dosage recommendations, and best practices to maximize the benefits of this revolutionary product.Tune in to "Maximizing Crop Yields with EmaGuard 5X" and learn how this cutting-edge insecticide can help you unlock the full potential of your fields, ensuring healthier crops and higher yields. Don't miss this in-depth discussion on taking your farming game to the next level!

Maximizing Crop Yields with EmaGuard 5X

Все про насіння, ЗЗР, цифрове землеробство, технічну експертизу та багато іншого... у Подкастах BASF

Все про насіння, ЗЗР, цифрове землеробство, технічну експертизу та багато іншого... у Подкастах BASF

BASF Аграрні Рішення Україна

NotebookLM "Deep Dives" into my research articles. NotebookLM is a free service (as of February 2025) from Google, that allows anyone to upload up to 50 documents (PDF, text files, etc.) into an online "Notebook" and use AI to extract information from them.In particular, one of the fun features of NotebookLM is its ability to generate an imaginary conversation between two protagonists about these documents.I have used this feature to obtain a lay-person's overview of some of my current and past research articles and found out that, even though they might miss some of the technical details, these discussions are in general fairly entertaining, while faithful to the original material... up to a certain point.Some of the imaginary applications of these studies are frankly science-fictional and sometimes hilariously fantastical.But who knows, maybe not? Note: each episode is automatically deleted after 90 days.

NotebookLM "Deep Dives" into my research articles. NotebookLM is a free service (as of February 2025) from Google, that allows anyone to upload up to 50 documents (PDF, text files, etc.) into an online "Notebook" and use AI to extract information from them. In particular, one of the fun features of NotebookLM is its ability to generate an imaginary conversation between two protagonists about these documents. I have used this feature to obtain a lay-person's overview of some of my current and past research articles and found out that, even though they might miss some of the technical details, these discussions are in general fairly entertaining, while faithful to the original material... up to a certain point. Some of the imaginary applications of these studies are frankly science-fictional and sometimes hilariously fantastical. But who knows, maybe not? Note: each episode is automatically deleted after 90 days.

Xavier Michalet's Podcast

On “Rare Insights” we bridge the gap between those living with rare diseases and the biopharmaceutical industry. Know Rare amplifies the voices of individuals with rare conditions, providing invaluable perspectives to accelerate therapeutic solutions. 

Join us as we dive deep into the complexities of rare diseases, exploring real-world insights from passionate industry leaders. Together, we navigate the unknowns and unlock the potential for groundbreaking treatments. Because in this journey, we’re all rare, sharing unique insights and experiences that drive innovation and progress.

Our host is Taren Grom, a well-respected media executive, who co-founded and then sold PharmaVoice, the preeminent trade magazine for life science executives at all stages of their careers. PharmaVoice focused on humanizing the people behind the science, a similar sensibility to Know Rare.


If you are in the biopharma industry and would like  more information about Know Rare,  visit knowrare.com/sponsors. Any questions, episode ideas, guest pitches, or comments can be sent into podcast@knowrare.com. For our blog and other podcasts and video content, visit knowrare.com.

Be sure to follow us on social media! We are @KnowRare on Instagram, X, and LinkedIn. 

Please rate and review the podcast on Apple, Spotify, or wherever you listen. This truly helps us climb the charts and allow more bio-pharmaceutical executives and other industry leaders, like yourself, to discover the show.

Rare Insights’ team includes Taren Grom, Liz Kay, Kaitlyn Taylor, DNA Today’s Kira Dineen, and Nina Wachsman, CEO and co-founder of Know Rare. 

We hope you enjoy listening to Rare Insights. Join us to uncover the future of rare disease treatment.

On “Rare Insights” we bridge the gap between those living with rare diseases and the biopharmaceutical industry. Know Rare amplifies the voices of individuals with rare conditions, providing invaluable perspectives to accelerate therapeutic solutions. Join us as we dive deep into the complexities of rare diseases, exploring real-world insights from passionate industry leaders. Together, we navigate the unknowns and unlock the potential for groundbreaking treatments. Because in this journey, we’re all rare, sharing unique insights and experiences that drive innovation and progress. Our host is Taren Grom, a well-respected media executive, who co-founded and then sold PharmaVoice, the preeminent trade magazine for life science executives at all stages of their careers. PharmaVoice focused on humanizing the people behind the science, a similar sensibility to Know Rare. If you are in the biopharma industry and would like more information about Know Rare, visit knowrare.com/sponsors. Any questions, episode ideas, guest pitches, or comments can be sent into podcast@knowrare.com. For our blog and other podcasts and video content, visit knowrare.com. Be sure to follow us on social media! We are @KnowRare on Instagram, X, and LinkedIn. Please rate and review the podcast on Apple, Spotify, or wherever you listen. This truly helps us climb the charts and allow more bio-pharmaceutical executives and other industry leaders, like yourself, to discover the show. Rare Insights’ team includes Taren Grom, Liz Kay, Kaitlyn Taylor, DNA Today’s Kira Dineen, and Nina Wachsman, CEO and co-founder of Know Rare. We hope you enjoy listening to Rare Insights. Join us to uncover the future of rare disease treatment.

Rare Insights: Uncovering The Future Of Rare Disease Treatments

Canal dedicado a la divulgación científica en el área de ingeniería química y procesos sustentables.  ¡¡¡¡¡Ven a descubrir esta maravillosa disciplina!!!!!

Canal dedicado a la divulgación científica en el área de ingeniería química y procesos sustentables. ¡¡¡¡¡Ven a descubrir esta maravillosa disciplina!!!!!

Chemistry Podcasts / Page 5